HM2017-02 A randomized, double-blind, placebo-controlled

  • Bejanyan, Nelli (PI)

Project: Research project

Project Details

Description

HM2017-02 A randomized, double-blind, placebo-controlled phase 2 study of vadastuximab talirine (SGNCD33A) in combination with cytarabine and daunorubicin (7+3) induction chemotherapy for newlydiagnosed acute myeloid leukemia patients (SGN33A-006)
StatusFinished
Effective start/end date1/1/1710/1/17

Funding

  • Seattle Genetics, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.